Are next-generation psychedelics the way forward for addressing treatment resistant depression?

Treatment resistant depression is framed as a major unmet need, even though standard antidepressants such as SSRIs help many people. The episode argues that next generation psychedelic-based therapies may offer a path forward, especially for patients with limited options. Beckley PsyTech is presented as a key example, focusing on next-generation psychedelic based compounds given in short clinic visits every two months. The discussion highlights BPL-003 and the company’s Phase 2b study results, with attention to how intranasal delivery is intended to improve administration. The episode also addresses safety considerations, including suicide related signals and other adverse events, and considers broader uses of psychedelics beyond depression. It compares Beckley PsyTech with other companies such as Compass Pathways and GH Research, and covers regulatory hurdles and stigma, including Beckley PsyTech’s partnership with atai Life Sciences.